{"nctId":"NCT01708902","briefTitle":"Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients","startDateStruct":{"date":"2012-10"},"conditions":["Diabetes Mellitus, Type 2"],"count":876,"armGroups":[{"label":"linagliptin2.5mg / metformin500mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: linagliptin 5mg","Drug: Metformin 500mg"]},{"label":"linagliptin2.5mg / metformin1000mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: linagliptin 5mg","Drug: Metformin 1000mg"]},{"label":"metformin 500mg BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: linagliptin2.5mg/metformin500mg"]},{"label":"metformin 1000mg BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: linagliptin2.5mg/metformin1000mg"]},{"label":"linagliptin 5 mg QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: linagliptin2.5mg/metformin1000mg","Drug: linagliptin2.5mg/metformin500mg"]}],"interventions":[{"name":"linagliptin2.5mg/metformin1000mg","otherNames":[]},{"name":"linagliptin2.5mg/metformin1000mg","otherNames":[]},{"name":"linagliptin 5mg","otherNames":[]},{"name":"Metformin 500mg","otherNames":[]},{"name":"linagliptin2.5mg/metformin500mg","otherNames":[]},{"name":"linagliptin2.5mg/metformin500mg","otherNames":[]},{"name":"linagliptin 5mg","otherNames":[]},{"name":"Metformin 1000mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of Type 2 diabetes mellitus(T2DM) prior to informed consent\n2. Male and female patients on diet and exercise regimen who are drug-naïve\n3. Glycosylated haemoglobin A1c (HbA1c) at V1a \\>/=7.5 %\\<11% for main group and HbA1c \\>/= 11.0 % for the additional parallel group\n4. Age \\>/= 18 and \\</= 80 years at Visit 1a (Screening)\n5. Body Mass Index(BMI)\\</ = 40 kg/m2 at Visit 1a (Screening)\n6. Signed and dated written informed consent by date of Visit 1a in accordance with good clinical practice(GCP) and local legislation\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycaemia required for rescue medication during placebo run-in phase\n2. In main group, the patients with investigational medicinal product(IMP) compliance \\< 80 % or \\>120 % during 2 weeks placebo run in period\n3. Acute coronary syndrome stroke or Transient ischaemic attack (TIA) within 3 months prior to randomisation\n4. Impaired hepatic function, defined by serum levels of either Alanine aminotransferase(ALT) ,Aspartate aminotransferase(AST), or alkaline phosphatase (AP) above 3 x upper limit of normal (ULN) ,or total bilirubin above 1.5 x ULN as determined at Visit 1a\n5. Known hypersensitivity or allergy to linagliptin or its excipients or metformin or placebo\n6. Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening\n7. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.\n8. Concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form or during the trial.\n9. Pre-menopausal women (last menstruation \\</= 1 year prior to informed consent) who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study\n10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.\n11. Renal failure or renal impairment at Visit 1a (screening) with an Estimated Glomerular Filtration Rate(eGFR) \\< 60 ml/min\n12. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption\n13. Dehydration by clinical judgement of the investigator\n14. Clinical detected unstable or acute congestive heart failure\n15. Acute or chronic metabolic acidosis (present in patient history)\n16. Hereditary galactose intolerance\n17. Known history of pancreatitis and chronic pancreatitis\n18. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within last 5 years.\n19. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial at the discretion of investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group","description":"The change from baseline in HbA1c after 24 weeks of treatment in main group.\n\nThe mean was adjusted by baseline HbA1c and treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.29","spread":"0.08"},{"groupId":"OG001","value":"-1.64","spread":"0.08"},{"groupId":"OG002","value":"-2.07","spread":"0.08"},{"groupId":"OG003","value":"-2.15","spread":"0.08"},{"groupId":"OG004","value":"-2.29","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group","description":"The occurrence of treat to target efficacy response in terms of HbA1c \\< 7.0 % after 24 weeks of treatment in main group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"69.0","spread":null},{"groupId":"OG003","value":"72.1","spread":null},{"groupId":"OG004","value":"77.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG","description":"The occurrence of treat to target efficacy response in terms of HbA1c \\< 7.0 % after 12 weeks of treatment in APG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":null},{"groupId":"OG001","value":"58.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group","description":"The occurrence of treat to target efficacy response in terms of HbA1c \\< 6.5% after 24 weeks of treatment in main group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null},{"groupId":"OG001","value":"34.7","spread":null},{"groupId":"OG002","value":"50.4","spread":null},{"groupId":"OG003","value":"56.3","spread":null},{"groupId":"OG004","value":"60.3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG","description":"The occurrence of treat to target efficacy response in terms of HbA1c \\< 6.5% after 12 weeks of treatment in APG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"36.8","spread":null}]}]}]},{"type":"PRIMARY","title":"The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)","description":"The change from baseline in HbA1c after 24 weeks of treatment in main group. Only subjects from the FAS with measured HbA1c values (observed cases \\[OC\\]) were considered.\n\nThe mean was adjusted by treatment, baseline HbA1c, week and treatment\\*week.\n\nThe sensitivity analysis was added as the primary analysis failed with borderline results.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"0.08"},{"groupId":"OG001","value":"-1.68","spread":"0.08"},{"groupId":"OG002","value":"-2.08","spread":"0.08"},{"groupId":"OG003","value":"-2.16","spread":"0.08"},{"groupId":"OG004","value":"-2.38","spread":"0.08"}]}]}]},{"type":"PRIMARY","title":"The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG","description":"The change from baseline in HbA1c after 12 weeks of treatment in additional parallel group (APG)\n\nThe mean was adjusted by baseline HbA1c and treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.46","spread":"0.22"},{"groupId":"OG001","value":"-4.71","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Relative Efficacy Response in Main Group","description":"The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) in main group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"80.6","spread":null},{"groupId":"OG002","value":"89.5","spread":null},{"groupId":"OG003","value":"93.0","spread":null},{"groupId":"OG004","value":"89.4","spread":null}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Relative Efficacy Response in APG","description":"The Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 12 Weeks of Treatment) in APG","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"91.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group","description":"The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment in main group.\n\nAdjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.03","spread":"2.25"},{"groupId":"OG001","value":"-29.87","spread":"2.23"},{"groupId":"OG002","value":"-42.07","spread":"2.31"},{"groupId":"OG003","value":"-39.33","spread":"2.24"},{"groupId":"OG004","value":"-47.44","spread":"2.26"}]}]}]},{"type":"SECONDARY","title":"The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG","description":"The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG.\n\nAdjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-56.70","spread":"6.53"},{"groupId":"OG001","value":"-91.92","spread":"6.48"}]}]}]},{"type":"SECONDARY","title":"The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group","description":"The frequency of patients with use of rescue therapy during 24 week treatment period in main group.\n\nFor this analysis the main group contrast 'Metformin 1000mg BID, Linagliptin 2.5mg / Metformin 1000mg BID' could not be analysed due to lack of events in the Metformin 1000mg BID group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"1.4","spread":null},{"groupId":"OG004","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG","description":"The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":147},"commonTop":["Hyperuricaemia","Diarrhoea","Upper respiratory tract infection","Hyperglycaemia","Dizziness"]}}}